These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 37600956)

  • 21. Prevalence and clinical characteristics of patients with metabolic dysfunction-associated fatty liver disease with hepatitis C virus infection-a population-based study.
    Attia D; Abdel Alem S; El-Akel W; Abdel-Razek W; Eslam M; Fouad Y; Waked I
    Aliment Pharmacol Ther; 2022 Dec; 56(11-12):1581-1590. PubMed ID: 36168675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
    van Kleef LA; Ayada I; Alferink LJM; Pan Q; de Knegt RJ
    Hepatology; 2022 Feb; 75(2):419-429. PubMed ID: 34453359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
    Kim D; Konyn P; Sandhu KK; Dennis BB; Cheung AC; Ahmed A
    J Hepatol; 2021 Dec; 75(6):1284-1291. PubMed ID: 34380057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic puzzle: Exploring liver fibrosis differences in Asian metabolic-associated fatty liver disease subtypes.
    Shaikh SS; Qazi-Arisar FA; Nafay S; Zaheer S; Shaikh H; Azam Z
    World J Hepatol; 2024 Jan; 16(1):54-64. PubMed ID: 38313248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact renaming non-alcoholic fatty liver disease to metabolic associated fatty liver disease in prevalence, characteristics and risk factors.
    Huang XJ; Yin M; Zhou BQ; Tan XY; Xia YQ; Qin CX
    World J Hepatol; 2023 Aug; 15(8):985-1000. PubMed ID: 37701916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic immune-inflammation index mediates the association between metabolic dysfunction-associated fatty liver disease and sub-clinical carotid atherosclerosis: a mediation analysis.
    Wang W; Guo XL; Qiu XP; Yu YJ; Tu M
    Front Endocrinol (Lausanne); 2024; 15():1406793. PubMed ID: 38957443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nomenclature Dilemma of Metabolic Associated Fatty Liver Disease (MAFLD): Considerable Proportions of MAFLD Are Metabolic Healthy.
    Park H; Yoon EL; Kim M; Cho S; Nah EH; Jun DW
    Clin Gastroenterol Hepatol; 2023 Apr; 21(4):1041-1049.e3. PubMed ID: 35504562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-invasive Screening of Metabolic Associated Fatty Liver Disease and Affecting Factors in Primary Care.
    Balci IC; Haciagaoglu N; Oner C; Cetin H; Simsek EE
    J Coll Physicians Surg Pak; 2023 Apr; 33(4):390-395. PubMed ID: 37190709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease.
    Dai YN; Xu CF; Pan HY; Huang HJ; Chen MJ; Li YM; Yu CH
    World J Clin Cases; 2022 May; 10(13):4097-4109. PubMed ID: 35665109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study.
    Hu Q; Chen Y; Bao T; Huang Y
    Ren Fail; 2022 Dec; 44(1):1996-2005. PubMed ID: 36374233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD.
    Yamamura S; Eslam M; Kawaguchi T; Tsutsumi T; Nakano D; Yoshinaga S; Takahashi H; Anzai K; George J; Torimura T
    Liver Int; 2020 Dec; 40(12):3018-3030. PubMed ID: 32997882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology.
    Peng D; Yu Z; Wang M; Shi J; Sun L; Zhang Y; Zhao W; Chen C; Tang J; Wang C; Ni J; Wen W; Jiang J
    Front Endocrinol (Lausanne); 2022; 13():935390. PubMed ID: 35928895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Analysis of advanced fibrosis in metabolic dysfunction-associated fatty liver disease patients with chronic hepatitis B].
    Wu X; Li P; Mi YQ
    Zhonghua Nei Ke Za Zhi; 2024 Jan; 63(1):53-58. PubMed ID: 38186118
    [No Abstract]   [Full Text] [Related]  

  • 35. Impact on Prevalence of the Application of NAFLD/MAFLD Criteria in Overweight and Normal Weight Patients.
    Ordoñez-Vázquez AL; Juárez-Hernández E; Zuarth-Vázquez JM; Ramos-Ostos MH; Uribe M; Castro-Narro G; López-Méndez I
    Int J Environ Res Public Health; 2022 Sep; 19(19):. PubMed ID: 36231529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of Hepatic Dendritic Cells in Liver Biopsies Showing Steatosis in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Associated with Obesity.
    Barranco-Fragoso B; Pal SC; Díaz-Orozco LE; Dorantes-Heredia R; Qi X; Méndez-Sánchez N
    Med Sci Monit; 2022 Aug; 28():e937528. PubMed ID: 35934868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.
    Tang SY; Tan JS; Pang XZ; Lee GH
    World J Gastroenterol; 2023 Jan; 29(3):549-560. PubMed ID: 36688021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma.
    Song BG; Choi SC; Goh MJ; Kang W; Sinn DH; Gwak GY; Paik YH; Choi MS; Lee JH; Paik SW
    JHEP Rep; 2023 Sep; 5(9):100810. PubMed ID: 37538246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Ability of Lipoprotein (a) Level to Predict Early Carotid Atherosclerosis Is Impaired in Patients With Advanced Liver Fibrosis Related to Metabolic-Associated Fatty Liver Disease.
    Wu T; Ye J; Shao C; Lin Y; Wang W; Feng S; Zhong B
    Clin Transl Gastroenterol; 2022 Jul; 13(7):e00504. PubMed ID: 35608296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The importance and impact of recognizing metabolic dysfunction-associated fatty liver disease in patients with chronic hepatitis C.
    Al-Omary A; Byth K; Weltman M; George J; Eslam M
    J Dig Dis; 2022 Jan; 23(1):33-43. PubMed ID: 34902220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.